Table 2

Results of treatment in the cyanoacrylate and β-blocker groups

CharacteristicsCyanoacrylate group (n=33) (n, %)β-Blocker group (n=34) (n, %)p Value
Follow-up (months)26 (3–34)26 (3–34)
Rebleeding3/33 (10%)15/34 (44%)0.004
Bleed from GOV22/26 (8%)12/28 (36%)0.005
Bleed from IGV11/6 (16%)3/4 (75%)0.190
Increase in size of GV015/34 (44%)0.001
Decrease in size of GV33/33 (100%)00.001
Appearance of oesophageal varix7/33 (21%)4/34 (11%)0.302
Aggravation/appearance of PHG8/33 (24%)7/34 (21%)1
Bleed-related mortality0/336/34 (17%)0.024
Overall mortality1/33 (3%)8/34 (23%)0.046
GOV20/266/28 (21%)0.023
IGV11/6 (16%)2/4 (50%)0.5
Complications1 (3%)2 (6%)1
  • GOV2, gastro-oesophageal varix type 2; GV, gastric varix; IGV1, isolated gastric varix type 1; PHG, portal hypertensive gastropathy.